Comparative Study on Clinical Efficacy and Safety of Different Doses of Tacrolimus Eye Drops in the Treatment of Patients with Keratoconjunctivitis
OBJECTIVE:To probe into clinical efficacy and safety of different doses of tacrolimus eye drops in the treatment of patients with keratoconjunctivitis.METHODS:A randomized,open cohort study was adopted.Totally 89 patients with keratoconjunctivitis admitted into Hubei Third People's Hospital Affiliated to Jianghan University from Mar.2021 to Mar.2023 were extracted to be divided into low-dose group(n=44)and conventional dose group(n=45)by random number table method.Tacrolimus eye drops were used once a day in the low-dose group and twice a day in the conventional dose group.All patients were treated continuously for 6 months.The scores of ocular symptoms and signs were compared between two groups before treatment,after treatment of 1 month,3 months and 6 months.The inflammation levels[C-reactive protein(CRP),interleukin(IL)-2,IL-6],best corrected vision and intraocular pressure(IOP)were compared between two groups before treatment and after treatment of 6 months.The clinical efficacy and adverse events were compared between two groups.RESULTS:After treatment of 1 month and 3 months,the scores of ocular symptoms and signs in the conventional dose group were significantly lower than those in the low-dose group,with statistically significant differences(P<0.05).After treatment of 6 months,there was no statistically significant difference between two groups in the scores of ocular symptoms and signs(P>0.05).After treatment of 6 months,there was no statistically significant difference in serum CRP,IL-2,IL-6,IOP and best corrected vision between two groups(P>0.05).The total effective rate of conventional dose group and low-dose group was respectively 91.11%(41/45)and 88.64%(39/44),with no statistically significant difference(P>0.05).The incidence of adverse events in the low-dose group was 4.55%(2/44),lower than 11.11%(5/45)in the conventional dose group,the difference was not statistically significant(P>0.05).CONCLUSIONS:The effects of low-dose tacrolimus in improving the clinical symptoms and signs of keratoconjunctivitis in the short term is less than that of conventional dose regimen,yet the long-term clinical efficacy is not affected,and the incidence of adverse events is lower when using low-dose tacrolimus,which has certain clinical application prospects.
TacrolimusKeratoconjunctivitisDifferent dosesAdverse drug reactions
国家科技期刊平台
NSTL
万方数据
